City Therapeutics, an early-stage developer of RNA interference (RNAi) drugs, prices its US initial public offering at $18 per share. Multiple outlets report that the IPO is upsized to raise about $200 million, with the final price set at the mid-point of the company’s marketed range. The funds are intended to support the company’s clinical and research programs.
Reporting across sources says the proceeds back a portfolio of medicines in or approaching clinical testing, alongside earlier work aimed at RNAi treatments designed to reach tissues beyond the liver. The outlets differ mainly in emphasis—some focus on the specific deal terms and pricing, while others highlight the drug pipeline and the scientific approach underlying the company’s platform.
